Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 6.96
EDAP's Cash-to-Debt is ranked lower than
99.99% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. EDAP: 6.96 )
Ranked among companies with meaningful Cash-to-Debt only.
EDAP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.37  Med: 3.1 Max: 12.46
Current: 6.96
0.37
12.46
Equity-to-Asset 0.53
EDAP's Equity-to-Asset is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. EDAP: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
EDAP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.5 Max: 0.73
Current: 0.53
0.25
0.73
Interest Coverage 0.08
EDAP's Interest Coverage is ranked lower than
99.99% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. EDAP: 0.08 )
Ranked among companies with meaningful Interest Coverage only.
EDAP' s Interest Coverage Range Over the Past 10 Years
Min: 0.08  Med: 7.26 Max: 7.63
Current: 0.08
0.08
7.63
Piotroski F-Score: 6
Altman Z-Score: 3.04
WACC vs ROIC
5.63%
17.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 1.04
EDAP's Operating Margin % is ranked lower than
99.99% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. EDAP: 1.04 )
Ranked among companies with meaningful Operating Margin % only.
EDAP' s Operating Margin % Range Over the Past 10 Years
Min: -18.31  Med: -11.32 Max: 1.51
Current: 1.04
-18.31
1.51
Net Margin % 11.20
EDAP's Net Margin % is ranked lower than
99.99% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. EDAP: 11.20 )
Ranked among companies with meaningful Net Margin % only.
EDAP' s Net Margin % Range Over the Past 10 Years
Min: -53.64  Med: -13.01 Max: 11.2
Current: 11.2
-53.64
11.2
ROE % 25.35
EDAP's ROE % is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. EDAP: 25.35 )
Ranked among companies with meaningful ROE % only.
EDAP' s ROE % Range Over the Past 10 Years
Min: -111.74  Med: -22.27 Max: 25.35
Current: 25.35
-111.74
25.35
ROA % 12.17
EDAP's ROA % is ranked lower than
99.99% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. EDAP: 12.17 )
Ranked among companies with meaningful ROA % only.
EDAP' s ROA % Range Over the Past 10 Years
Min: -31.62  Med: -9.52 Max: 12.17
Current: 12.17
-31.62
12.17
ROC (Joel Greenblatt) % 149.55
EDAP's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. EDAP: 149.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EDAP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -65.88  Med: -24.1 Max: 149.55
Current: 149.55
-65.88
149.55
3-Year Revenue Growth Rate -7.20
EDAP's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. EDAP: -7.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EDAP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.3  Med: -3.4 Max: 10.9
Current: -7.2
-17.3
10.9
GuruFocus has detected 1 Warning Sign with Edap TMS SA $EDAP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EDAP's 30-Y Financials

Financials (Next Earnings Date: 2017-08-17 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

EDAP Guru Trades in Q2 2016

Robert Bruce 1,045,494 sh (unchged)
» More
Q3 2016

EDAP Guru Trades in Q3 2016

Robert Bruce 1,045,494 sh (unchged)
» More
Q4 2016

EDAP Guru Trades in Q4 2016

Robert Bruce 1,045,494 sh (unchged)
» More
Q1 2017

EDAP Guru Trades in Q1 2017

Robert Bruce 1,045,494 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with EDAP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:SPAN, NAS:DRAD, NAS:IRMD, NAS:MSON, NAS:EYES, NAS:NVTR, NAS:CGNT, NAS:IRIX, OTCPK:TITXF, NAS:SRTS, OTCPK:IVOB, NAS:PAVM, OTCPK:BTCY, OTCPK:PHMZF, OTCPK:BLOZF, NAS:NVCN, OTCPK:AVMXF, NAS:TNDM, OTCPK:TLTFF, NAS:ACRX » details
Traded in other countries:EDA.Germany,
Headquarter Location:France
Edap TMS SA is a holding company. The Company through its divisions HIFU and UDS,develops, produces and markets minimally invasive medical devices for urological diseases. Its divisions operate in Europe, the Americas, Asia and the rest of the world.

Edap TMS SA was incorporated on December 3, 1979 as a Societe Anonyme organized under the laws of the Republic of France for 60 years from the date of incorporation. It is a holding Company and is responsible for providing common services to its subsidiaries, including preparation and consolidation of the financial statements for the group, complying with the requirements of various regulatory agencies and maintaining the listing of its publicly held securities. Its activity is organized in two divisions: HIFU and UDS. Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases. It's HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. Its HIFU business is quite seasonal and generally linked to lengthy hospital decision and investment processes. In addition to developing, manufacturing and marketing HIFU devices, the HIFU division also generates revenues from leasing equipment, as well as from the sale of disposables, spare parts and maintenance services. Currently, the only commercial product of the Company utilizing HIFU technology is the Ablatherm, an ultrasound guided HIFU device for the treatment of organ-confined prostate cancer. As of December 31, 2013, the HIFU division's patent portfolio contained 36 patents consisting of 16 in the United States, 18 in the European Union and Japan and 2 in Israel and the rest of the world. The Company belongs to 18 groups of patents covering key technologies related to therapeutic ultrasound principles, systems and associated software. The UDS division's main business is producing and marketing devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology. In addition to its manufacturing and selling of lithotripters, the UDS division also generates revenues from the leasing of lithotripters, as well as from the sale of disposables, spare parts and maintenance services. The UDS division offers the Sonolith i-move to small and mid-size hospitals, while the Sonolith i-sys is offered to large hospitals that can afford a fully dedicated and integrated lithotripter. Ablatherm-HIFU device competes with all current treatments for localized tumors, which include surgery, brachytherapy, radiotherapy, cryotherapy and hormonotherapy. The Company and its products are regulated in the United States by the FDA under a number of statutes including the Federal Food, Drug and Cosmetic Act.

Top Ranked Articles about Edap TMS SA

EDAP Announces Ablatherm Fusion World Premiere during American Urology Association Annual Meeting in Boston, MA, May 12-16, 2017
EDAP TMS SA to Report First Quarter 2017 Financial Results on May 17, 2017
EDAP Achieves 63% Growth in HIFU Revenue in 2016
EDAP's Ablatherm® Robotic HIFU: Clinical Results Support High-Intensity Focused Ultrasound (HIFU) for Prostate Tissue Ablation after Unsuccessful Radiotherapy

Multicenter Retrospective Analysis of 418 Patients  LYON, France, March 22, 2017 -- EDAP TMS SA ( EDAP), the global leader in therapeutic ultrasound, today announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic HIFU for prostate tissue ablation in patients who had previously undergone radiotherapy treatment. The article concludes that HIFU should be considered as a valuable therapeutic option for carefully selected patients who failed a previous radiotherapy treatment. The article has been published in the January 2017 edition of the prestigious peer-reviewed British Journal of Urology International. Authored by Pr. Sébastien Crouzet, M.D., Ph.D., from Edouard Herriot Hospital, Lyon, France, and co-authored by lead urologists from nine institutions across France, Germany, UK, Italy and the USA, this retrospective analysis was designed to evaluate the outcomes of Ablatherm Robotic HIFU for the treatment of patients who had been previously treated with radiotherapy and were indicated for additional prostate tissue ablation. The results were compiled from the Ablatherm treatment registry (@-RegistryTM), a multicenter secure online database for patients who have undergone prostate HIFU with Ablatherm. Inclusion criteria for the analysis were applied to the database, resulting in 418 patients with available data. Statistical models were applied to the data, using the longest available follow-up timepoint for each outcome and patient. Based on the Kaplan Meier survivorship analysis of this data, the rates of overall survival, cancer specific survival, and metastasis free survival at 7 years were 72%, 82%, and 81%, respectively. Pr. Sébastien Crouzet commented: "This is the largest series of salvage patients treated with HIFU and followed for data collection. The results are encouraging, and support the use of Ablatherm Robotic HIFU for these patients who are particularly fragile after the failure of their radiation treatment and are limited to minimally invasive treatment options. Patients who require additional treatment after a radiation therapy may benefit from prostate tissue ablation with HIFU." Marc Oczachowski, Chief Executive Officer of EDAP TMS, added: "There is a growing number of patients who failed their radiotherapy treatment and require a secondary option; this large and growing market opportunity is the result of an as-yet unmet medical need. Pr. Sébastien Crouzet's clinical publication reconfirms that EDAP's Ablatherm HIFU technology offers a valuable answer to this need and is well positioned to serve this growing population with minimal competition." Link to e-publication abstract: http://onlinelibrary.wiley.com/doi/10.1111/bju.13766/abstract About EDAP TMS SA EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm is approved for commercial distribution in Europe and other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com. Forward-Looking Statements In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Investor Contact CG CAPITAL
Rich Cockrell
877.889.1972
[email protected] Company Contact Blandine Confort
Investor Relations / Legal Affairs EDAP TMS SA
33 4 72 15 31 50
[email protected]


Read more...
EDAP TMS SA to Report Fourth Quarter and Full Year 2016 Results on April 3, 2017

EDAP TMS SA to Report Fourth Quarter and Full Year 2016 Results on April 3, 2017 LYON, France, March 14, 2017 - EDAP TMS SA ( EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2016, after the close of the financial markets on Monday, April 3, 2017. An accompanying conference call will be conducted by Marc Oczachowski, Chief Executive Officer, and Francois Dietsch, Chief Financial Officer, to go over the results. The call will be held at 8:30 AM ET, on Tuesday, April 4, 2017. Please refer to the information below for conference call dial-in information and webcast registration. Conference Details Conference Date: Tuesday, April 4, 2017 8:30 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: EDAP-TMS Fourth Quarter and Full Year 2016 Results Call
Webcast Registration: Click Here Following the live call, a replay will be available on the Company's website, www.edap-tms.com under "Investors Information." About EDAP TMS SA EDAP TMS SA today markets Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico, Chile, Brazil and Canada, and has received 510(k) clearance by the U.S. FDA. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com. Important Cautions Regarding Forward-looking Statements In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved.
Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Investor Contact CG CAPITAL
Rich Cockrell
877.889.1972
[email protected] Company Contact Blandine Confort
Investor Relations / Legal Affairs EDAP TMS SA
33 4 72 15 31 50
[email protected]


Read more...
EDAP's Long Term Academic HIFU Partner INSERM LabTAU Designated Center of Excellence by the Focused Ultrasound Foundation

LYON, France, March 8, 2017 -- EDAP TMS SA ( EDAP), the global leader in therapeutic ultrasound, today announced that the prestigious Focused Ultrasound Foundation, based in Charlottesville, VA, designated long-term academic French partner INSERM LabTAU a Center of Excellence. EDAP and INSERM Laboratory of Therapeutic Applications of Ultrasound (LabTAU), in conjunction with the University Hospital Edouard Herriot in Lyon, have been collaborating closely for the past 27 years in the development and use of therapeutic ultrasound in the treatment of kidney stones and localized prostate cancer. These strategic interfaces resulted in the successful marketing of Sonolith®, Ablatherm® Robotic-HIFU and Focal One® worldwide. So far, more than 45,000 prostate cancer patients have been treated using our HIFU technology. EDAP and INSERM LabTAU are currently pursuing on-going development projects using HIFU for therapeutic applications beyond prostate cancer. Dr. Cyril Lafon, Ph.D., Director of LabTAU, commented: "INSERM LabTAU and EDAP privileged partnership is a valuable example of a fruitful and successful cooperation between academic scientists and a medical device company. Our expertise and advancements are complementary thus accelerating the availability of such non-invasive technology as HIFU to patients." "LabTAU at INSERM is a pioneering site for research and development in focused ultrasound. They have a long history of establishing how focused ultrasound interacts with tissue, and they use that information to develop innovative clinical applications," says Foundation Chairman Neal F. Kassell, MD. "Their laboratory research has resulted in a number of commercially available products -- including those used for the first focused ultrasound treatment for patients with prostate cancer." Marc Oczachowski, EDAP TMS Chief Executive Officer, concluded: "We are very enthusiastic and proud of the nomination of our privileged partner INSERM LabTAU as Center of Excellence by the prestigious Focused Ultrasound Foundation. It is a recognition of INSERM's highly qualified research work on therapeutic ultrasound. The designation validates our successful collaboration in developing HIFU and ensuring that our co-advancements benefit patients. We at EDAP remain dedicated to making HIFU a standard of care in the treatment of particular types of tumors." For more information on the designation of INSERM LabTAU as Center of Excellence, please refer to the Focused Ultrasound release: https://www.fusfoundation.org/news/1882-new-center-of-excellence-focuses-on-collaborations-and-education. About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm is approved for commercial distribution in Europe and other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com. About INSERM LabTAU The laboratory LabTAU for Laboratory of Therapeutic Applications of Ultrasound (Claude Bernard Lyon 1 University and INSERM Unit 1032), under the direction of Cyril Lafon, is specialized in the development of non-invasive or minimally invasive therapeutic applications of image-guided ultrasound, by combining experimental and theoretical research for which very few teams, even international, possess the required know-how. Since January 1, 2005, the laboratory has produced 198 publications in referred journals and 190 communications, including 22 invited communications. Technological or methodological expertise of the team and its partners covers the entire range of investigations from the bench to the bedside. The research on ultrasound therapy conducted in LabTAU is widely regarded as being at the forefront of worldwide developments in this field leading to international activity by means of several actions: reception of foreign researchers, European actions, bilateral collaboration contracts, thesis co-supervision. For more information on INSERM LabTAU, please visit: http://labtau.univ-lyon1.fr/. About The Focused Ultrasound Foundation The Focused Ultrasound Foundation (FUSF) is a non-profit organization based in Charlottesville, Virginia, United States, dedicated to accelerating the development and adoption of focused ultrasound. Its main areas of involvement and support are research, collaboration, education and advocacy. In 2009, the Foundation created the Centers of Excellence program which brings together the best people and technical resources at luminary sites to showcase the technology and serve as hubs for collaboration. For more information on the Foundation, please visit https://www.fusfoundation.org. Forward-Looking Statements In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Investor Contact CG CAPITAL
Rich Cockrell
877.889.1972
[email protected] Company Contact Blandine Confort
Investor Relations / Legal Affairs EDAP TMS SA
33 4 72 15 31 50
[email protected]


Read more...
EDAP Appoints Vice-President of Global Medical, Regulatory and Quality Affairs in the U.S.

EDAP Appoints Vice-President of Global Medical, Regulatory and Quality Affairs in the U.S. LYON, France, March 6, 2017 -- EDAP TMS SA ( EDAP), the global leader in therapeutic ultrasound, today announced the appointment of Noah J. Bartsch as Vice President of Global Medical, Regulatory, and Quality Affairs. 
Mr. Bartsch will be responsible for leading EDAP's Medical, Regulatory, and Quality Affairs operations in the United States to expand and execute the strategy to advance High-Intensity Focused Ultrasound (HIFU) technology adoption and recognition. This will include managing U.S. Food and Drug Administration (FDA) developments, initiating reimbursement coverage for HIFU, and collaborating with Key Opinion Leaders. He will also lead EDAP's clinical research and regulatory submission strategies worldwide and will be based in EDAP's U.S. headquarters in Austin, Texas. In this position, Mr. Bartsch will become a member of the Global Executive Team for EDAP. Prior to joining EDAP, Mr. Bartsch was the Global Vice President of Clinical, Regulatory, and Quality Affairs at LDR ( LDRH) where he spent the last 10 years supporting the growth of the French start-up orthopedic spine company into a U.S. market leader. LDR was acquired in July 2016 for one billion U.S. dollars. While at LDR, he worked extensively with the FDA, leading the Premarket Approval (PMA) submission process and obtaining approval of two PMAs for Class III indications. He managed the related Investigational Device Exemption (IDE) studies and led the clinical publication strategies that supported market adoption and reimbursement coverage. He also achieved several U.S. 510(k) market clearances.  His efforts in quality affairs resulted in a mature quality system functioning globally while maintaining compliance with regulations and quality standards worldwide. Noah Bartsch commented: "There is an opportunity to advance the adoption and utility of HIFU in the United States, along with the rest of the world, as patients and physicians demand less invasive treatments that improve quality of life.  EDAP's technology is very promising and will require continued collaboration with regulatory agencies, insurance providers, and physician users. I am excited to join EDAP at this phase in the company's history and to ultimately provide properly indicated patients with additional treatment options." Marc Oczachowski, EDAP Chief Executive Officer, added: "We are extremely pleased to have Noah join EDAP's Global Executive Team. With his impressive background and participation in LDR's success, Noah will bring his extensive experience to our clinical and regulatory global developments. Based in the U.S headquarters in Austin, Texas, he will contribute strongly to our U.S. expansion while ensuring continued quality excellence worldwide." About EDAP TMS SA EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm is approved for commercial distribution in Europe and other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com. Forward-Looking Statements In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Investor Contact CG CAPITAL Rich Cockrell 877.889.1972 [email protected] Company Contact Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA 33 4 72 15 31 50 [email protected]


Read more...

Ratios

vs
industry
vs
history
PE Ratio 23.08
EDAP's PE Ratio is ranked lower than
99.99% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. EDAP: 23.08 )
Ranked among companies with meaningful PE Ratio only.
EDAP' s PE Ratio Range Over the Past 10 Years
Min: 5.1  Med: 22.57 Max: 52.09
Current: 23.08
5.1
52.09
PE Ratio without NRI 23.08
EDAP's PE Ratio without NRI is ranked lower than
99.99% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. EDAP: 23.08 )
Ranked among companies with meaningful PE Ratio without NRI only.
EDAP' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.03  Med: 22.57 Max: 52.09
Current: 23.08
5.03
52.09
PB Ratio 3.36
EDAP's PB Ratio is ranked lower than
99.99% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. EDAP: 3.36 )
Ranked among companies with meaningful PB Ratio only.
EDAP' s PB Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.79 Max: 18.27
Current: 3.36
0.49
18.27
PS Ratio 2.26
EDAP's PS Ratio is ranked lower than
99.99% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. EDAP: 2.26 )
Ranked among companies with meaningful PS Ratio only.
EDAP' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 1.6 Max: 4.74
Current: 2.26
0.31
4.74
EV-to-EBIT 7.55
EDAP's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. EDAP: 7.55 )
Ranked among companies with meaningful EV-to-EBIT only.
EDAP' s EV-to-EBIT Range Over the Past 10 Years
Min: -5776  Med: -4.9 Max: 178.8
Current: 7.55
-5776
178.8
EV-to-EBITDA 7.55
EDAP's EV-to-EBITDA is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. EDAP: 7.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
EDAP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5776  Med: -4.9 Max: 178.8
Current: 7.55
-5776
178.8
Current Ratio 2.70
EDAP's Current Ratio is ranked lower than
99.99% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. EDAP: 2.70 )
Ranked among companies with meaningful Current Ratio only.
EDAP' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 2.39 Max: 3.92
Current: 2.7
1.27
3.92
Quick Ratio 2.16
EDAP's Quick Ratio is ranked lower than
99.99% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. EDAP: 2.16 )
Ranked among companies with meaningful Quick Ratio only.
EDAP' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.91 Max: 3.38
Current: 2.16
1.07
3.38
Days Inventory 83.14
EDAP's Days Inventory is ranked lower than
99.99% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. EDAP: 83.14 )
Ranked among companies with meaningful Days Inventory only.
EDAP' s Days Inventory Range Over the Past 10 Years
Min: 83.14  Med: 107.9 Max: 136.7
Current: 83.14
83.14
136.7
Days Sales Outstanding 98.53
EDAP's Days Sales Outstanding is ranked lower than
99.99% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. EDAP: 98.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
EDAP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 98.53  Med: 182.24 Max: 249.93
Current: 98.53
98.53
249.93
Days Payable 101.27
EDAP's Days Payable is ranked lower than
99.99% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. EDAP: 101.27 )
Ranked among companies with meaningful Days Payable only.
EDAP' s Days Payable Range Over the Past 10 Years
Min: 101.27  Med: 121.68 Max: 171.02
Current: 101.27
101.27
171.02

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.70
EDAP's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. EDAP: -9.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EDAP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23  Med: -7.2 Max: 2.9
Current: -9.7
-23
2.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 4.48
EDAP's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. EDAP: 4.48 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
EDAP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.29  Med: 3.4 Max: 19.45
Current: 4.48
0.29
19.45
Price-to-Tangible-Book 3.75
EDAP's Price-to-Tangible-Book is ranked lower than
99.99% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. EDAP: 3.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EDAP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.22  Med: 2.19 Max: 8.66
Current: 3.75
0.22
8.66
Price-to-Intrinsic-Value-Projected-FCF 4.41
EDAP's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. EDAP: 4.41 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EDAP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.41  Med: 2.61 Max: 4.56
Current: 4.41
0.41
4.56
Price-to-Median-PS-Value 1.41
EDAP's Price-to-Median-PS-Value is ranked lower than
99.99% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. EDAP: 1.41 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EDAP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 0.83 Max: 1.95
Current: 1.41
0.17
1.95
Price-to-Graham-Number 1.97
EDAP's Price-to-Graham-Number is ranked lower than
99.99% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. EDAP: 1.97 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EDAP' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.08  Med: 0.44 Max: 4.67
Current: 1.97
0.08
4.67
Earnings Yield (Greenblatt) % 13.23
EDAP's Earnings Yield (Greenblatt) % is ranked lower than
100% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. EDAP: 13.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EDAP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.6  Med: 6.5 Max: 189209.4
Current: 13.23
0.6
189209.4

More Statistics

Revenue (TTM) (Mil) $39.18
EPS (TTM) $ 0.13
Beta0.80
Short Percentage of Float0.00%
52-Week Range $2.25 - 3.62
Shares Outstanding (Mil)28.73

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 44 49 55
EPS ($) -0.09 -0.03 0.03
EPS without NRI ($) -0.09 -0.03 0.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for EDAP

Headlines

Articles On GuruFocus.com
EDAP Announces Ablatherm Fusion World Premiere during American Urology Association Annual Meeting in May 11 2017 
EDAP TMS SA to Report First Quarter 2017 Financial Results on May 17, 2017 May 02 2017 
EDAP Achieves 63% Growth in HIFU Revenue in 2016 Apr 03 2017 
EDAP's Ablatherm® Robotic HIFU: Clinical Results Support High-Intensity Focused Ultrasound (HI Mar 22 2017 
EDAP TMS SA to Report Fourth Quarter and Full Year 2016 Results on April 3, 2017 Mar 14 2017 
EDAP's Long Term Academic HIFU Partner INSERM LabTAU Designated Center of Excellence by the Focused Mar 08 2017 
EDAP Appoints Vice-President of Global Medical, Regulatory and Quality Affairs in the U.S. Mar 06 2017 

More From Other Websites
EDAP Announces CMS Approval of New Reimbursement Code for HIFU Ablation of the Prostate May 22 2017
EDAP TMS SA Reports First Quarter 2017 Results May 17 2017
Implied Volatility Surging for EDAP TMS (EDAP) Stock Options May 16 2017
EDAP Announces Ablatherm Fusion World Premiere during American Urology Association Annual Meeting in... May 11 2017
EDAP TMS SA :EDAP-US: Earnings Analysis: For the six months ended December 31, 2016 : April 11, 2017 Apr 11 2017
New Strong Sell Stocks for April 11th Apr 11 2017
EDAP Achieves 63% Growth in HIFU Revenue in 2016 Apr 03 2017
EDAP's Ablatherm® Robotic HIFU: Clinical Results Support High-Intensity Focused Ultrasound (HIFU)... Mar 22 2017
EDAP TMS SA to Report Fourth Quarter and Full Year 2016 Results on April 3, 2017 Mar 14 2017
EDAP's Long Term Academic HIFU Partner INSERM LabTAU Designated Center of Excellence by the Focused... Mar 08 2017
EDAP Appoints Vice-President of Global Medical, Regulatory and Quality Affairs in the U.S. Mar 06 2017
EDAP's Ablatherm® Robotic HIFU Treatments Performed at University of Minnesota Feb 27 2017
EDAP Announces Preliminary Unaudited Full Year 2016 Revenue Feb 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat